Contents

Review

887  EULAR study group on ‘MHC-I-opathy’: identifying disease-overarching mechanisms across disciplines and borders


Systemic lupus erythematosus

927  Machine learning identifies clusters of longitudinal autoantibody profiles predictive of systemic lupus erythematosus disease outcomes


Viewpoint

897  What is a response in randomised controlled trials in giant cell arthritis?

C Dajaco, S Ramiro, Z Tsouma, M Bond, M Sooowmer, C Sanchez-Arceaza, C A Langford

Vasculitis

937  Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial


Rheumatoid arthritis

901  Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled trial ORAL Surveillance

L E Kristensen, S Danelse, P Ydestad, C Wang, E Nagy, E Mosier, J Rivas, B Benda

Inflammatory arthritis

911  Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study

V Hius, H Bower, K Hellgren, T Frisch, J Asling, Behalf of the ARTIS group

2020 Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis


Autoimmunity

945  Rheumatoid factor autoantibody repertoire profiling reveals distinct binding epitopes in health and autoimmunity

N Oskoom, P Ooghe-De Heer, D Kos, J Jeremiass, L Van Beheim, G M Verspagen, F G M Kroese, D Van Schaardenburg, C Wolbink, T Rogens

More Contents
### Contents

**Epidemiology**

957  Incidence, prevalence and mortality of IgG4-related disease in the USA: a claims-based analysis of commercially insured adults  
Z S Wallace, C Miles, E Smolikina, N Petrussi-Vileva, D Madzica, C Cook, X Fu, Y Zhang, J H Stone, H K Choi

**Osteoarthritis**

963  Inhibition of KDM7A/B histone demethylases restores H3K79 methylation and protects against osteoarthritis  
R Assi, C Cherif, F M F Cornelis, Q Zhou, I Storms, S Pezzino, R Coutinho de Almeida, R J Lories, S Monteagudo

974  A meta-analysis and a functional study support the influence of mtDNA variant m.16519C on the risk of rapid progression of knee osteoarthritis  

**Osteoporosis**

985  Genome-wide association study identifies genetic variants which predict the response of bone mineral density to teriparatide therapy  
N Alonso, O M E Albagha, A Azfer, B Larraz-Prieto, K Berg, P L Riches, B Ostanek, T Kozan, J Marc, B L Langkahlb, S H Ralston

**Images in rheumatology**

992  Clinical image: synovitis of the metacarpophalangeal joints  
L van der Weeke, T Niissi, M Maas, P Don Critie, M Janssen, C Otto, T J Janssen, S W Tas, N de Vries

**Letters**

994  Baricitinib for juvenile idiopathic arthritis: a monocentric case series  
I Maccara, T Olivero, I Pazzini, E Marrani, M V Mastrolo, G Simonini

995  Complete resolution of gastric antral vascular ectasia after autologous haematopoietic stem cell transplantation in systemic sclerosis  
S Kerez, T Zuckerman, I Heng, T Rainis, S Odeh, N Arval, A Shrivast, G Slivodin, D Rinar

996  COVID-19 infection after autologous stem cell transplantation for systemic sclerosis  
J C Henes, I Almaraz, W Vogel, C Lengenke, R Klein, L Hosen, A C Pecher

**Electronic pages**

e153  Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’  
T Klopfenstein, V Gendrin, T Corrozzi, A Geratzie, M Poyraudeau, S Zayet

e154  Response to: ‘Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’’ by Klopfenstein et al  
R BM Landewe, S Ramiro, R L M Mostard

e155  Correspondence on ‘Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: a monocentric survey’  
P Montero, I Castrejón, J Martínez-Barró, J C Nieves-González, J Rivera, J M Álvarez-Gracia, J Molina Collada

e156  Response to ‘Correspondence on ‘Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: a monocentric survey’’ by Montero et al  
A Tomellini, L Dagna, C Camprosiao

e157  Correspondence on ‘Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry’ by Sparks et al  
E Gremese, G Ferraccioli

e158  Response to: Correspondence on ‘Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry’ by Sparks et al  
Z S Wallace, J A Sparks, P C Robinson, P M Machado, J Yazdany

e159  Correspondence on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry’ by Gianfrancesco M et al. The impact of cardiovascular comorbidity on COVID-19 infection in a large cohort of rheumatoid arthritis patients  
P Cazzaglia, A Mucidichi, G Erne, M Piga, G Sacchellariou, ombrettaaviggianta, E Gremese, F R Spinelli, F Atzeni, E Bartolini
Correspondence on ‘Role of joint damage, malalignment and inflammation in articular tenderness in rheumatoid arthritis, psoriatic arthritis and osteoarthritis’
Q A Dumoulin, X M E Matthijsen, F Wouters, D I Knijffeld, E Niemantsverdriet, A H M van der Helm-van Mil

Response to: ‘Correspondence on ‘Role of joint damage, malalignment and inflammation in articular tenderness in rheumatoid arthritis, psoriatic arthritis and osteoarthritis” by Dumoulin et al
I Gesol, D Aesthaa, P Mundl

Correspondence on ‘Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial’
S Jain, V Dhir

Response to: ‘Correspondence on ‘Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial” by Jain and Dhir et al
V Wouters, R W Westhovens, S Pazzino, D De Cock, K Van der Elst, J Joly, D Bertrand, P Verschueren

Correspondence on ‘Which factors are associated with bone marrow oedema suspicious of axial spondyloarthritis as detected by MRI in the sacroiliac joints and the spine in the general population?”
C-L Su, J-Wei Chen, J-C Wei

Response to: ‘Correspondence on ‘Which factors are associated with bone marrow oedema suspicious of axial spondyloarthritis as detected by MRI in the sacroiliac joints and the spine in the general population?” by Su et al
X Bataliskos, A Richter, C O Schmidt, J Braun

Correspondence on ‘Warfarin use and risk of knee and hip replacements’
N He, Z Fang, X Li, S Zhai

Response to: ‘Correspondence on: ‘Warfarin use and risk of knee and hip replacements” by He et al
P Ballal, C Peloquin, C G Boer, T Neogi

Correspondence on ‘Variants in urine transporters, ADH1B, GCKR and MEPE genes associated with transition from asymptomatic hyperuricaemia to gout: results of the first gout versus asymptomatic hyperuricaemia GWAS in Caucasians using data from the UK Biobank”
R Takei, N A Sumpter, A Phipps-Green, M Cadzow, R K Topless, R J Reynolds, T R Merimaa

Response to: ‘Correspondence on ‘Variants in urine transporters, ADH1B, GCKR and MEPE genes associated with transition from asymptomatic hyperuricaemia to gout: results of the first gout versus asymptomatic hyperuricaemia GWAS in Caucasians using data from the UK Biobank” by Takei et al
G Sandoval-Plaza, K Mrézin, A Akhaishek

Correspondence on ‘Classification criteria: time for a rethink’ by D Porter et al
H Yazici, Y Yazici